Transgene Receives MHRA Approval for Lead myvac™ Individualized Immunotherapy, TG4050, to Commence Clinical Development in HPV Negative Head and Neck Cancers in the UK

252

STRASBOURG, France–(BUSINESS WIRE)–Regulatory News: Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of solid tumors, today announces it has received the approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to proceed with a Phase 1 clinical trial of its lead myvacTM candidate TG4050. TG4050 is being developed as a potential treatment for patients with newly diagnosed, locoregionally advanced, HPV negat….

 

 

 

 

http://www.businesswire.com/news/home/20190710005650/en/Transgene-Receives-MHRA-Approval-Lead-myvac%E2%84%A2-Individualized

 

- Advertisement -